| Title: |
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial |
| Authors: |
Deanfield J.; Verma S.; Scirica B. M.; Kahn S. E.; Emerson S. S.; Ryan D.; Lingvay I.; Colhoun H. M.; Plutzky J.; Kosiborod M. N.; Hovingh G. K.; Hardt-Lindberg S.; Frenkel O.; Weeke P. E.; Rasmussen S.; Goudev A.; Lang C. C.; Urina-Triana M.; Pietilä M.; Lincoff A. M.; Abe M.; Abhaichand R. K.; Abhayaratna W. P.; Abhyankar A.; Abidin I. B. Z.; Abou Assi H.; Accini Mendoza J. L.; Adas M.; Agaiby J. M.; Agarwal D. K.; Agha M.; Ahmed A.; Ahtiainen P.; Aigner E.; Ajay N.; Ali N.; Al-Karadsheh A.; Allison R.; Allison D. C.; Alpenidze D.; Altuntas Y.; Al-Zoebi A.; Ambuj R.; Amerena J.; Anderson R. J.; Ando T.; Andrews R.; Antonova E.; Appel K. F.; Arantes F. B.; Araz M.; Arbel Y.; Arenas León J. L.; Argyrakopoulou G.; Ariani M.; Arias Mendoza M. A.; Arif A. A.; Arneja J.; Aroda V. R.; Aronne L. J.; Arstall M.; Asamoah N.; Asanin M.; Audish H.; Avram R.; Badat A.; Badiu C. V.; Bakdash W.; Bakiner O. S.; Bandezi V. N.; Bang L. H.; Bansal S.; Baranyai M.; Barbarash O.; Barber M.; Barnum O.; Barone Rochette G.; Bashkin A.; Baum S.; Bays H. E.; Bazzoni Ruiz A. E.; Beckowski M.; Beerachee Y.; Bellary S.; Belousova L.; Berk M.; Bernstein M.; Berra C.; Beshay I.; Bhagwat A.; Bhan A.; Biggs W. C.; Billings L.; Bitar F.; Block B.; Bo S.; Bogdanski P.; Bolshakova O. O.; Boshchenko A. A.; Bosworth H.; Buscemi S. |
| Contributors: |
Deanfield J.; Verma S.; Scirica B.M.; Kahn S.E.; Emerson S.S.; Ryan D.; Lingvay I.; Colhoun H.M.; Plutzky J.; Kosiborod M.N.; Hovingh G.K.; Hardt-Lindberg S.; Frenkel O.; Weeke P.E.; Rasmussen S.; Goudev A.; Lang C.C.; Urina-Triana M.; Pietilä M.; Lincoff A.M.; Abe M.; Abhaichand R.K.; Abhayaratna W.P.; Abhyankar A.; Abidin I.B.Z.; Abou Assi H.; Accini Mendoza J.L.; Adas M.; Agaiby J.M.; Agarwal D.K.; Agha M.; Ahmed A.; Ahtiainen P.; Aigner E.; Ajay N.; Ali N.; Al-Karadsheh A.; Allison R.; Allison D.C.; Alpenidze D.; Altuntas Y.; Al-Zoebi A.; Ambuj R.; Amerena J.; Anderson R.J.; Ando T.; Andrews R.; Antonova E.; Appel K.F.; Arantes F.B.; Araz M.; Arbel Y.; Arenas León J.L.; Argyrakopoulou G.; Ariani M.; Arias Mendoza M.A.; Arif A.A.; Arneja J.; Aroda V.R.; Aronne L.J.; Arstall M.; Asamoah N.; Asanin M.; Audish H.; Avram R.; Badat A.; Badiu C.V.; Bakdash W.; Bakiner O.S.; Bandezi V.N.; Bang L.H.; Bansal S.; Baranyai M.; Barbarash O.; Barber M.; Barnum O.; Barone Rochette G.; Bashkin A.; Baum S.; Bays H.E.; Bazzoni Ruiz A.E.; Beckowski M.; Beerachee Y.; Bellary S.; Belousova L.; Berk M.; Bernstein M.; Berra C.; Beshay I.; Bhagwat A.; Bhan A.; Biggs W.C.; Billings L.; Bitar F.; Block B.; Bo S.; Bogdanski P.; Bolshakova O.O.; Boshchenko A.A.; Bosworth H. |
| Publisher Information: |
ELSEVIER |
| Publication Year: |
2024 |
| Collection: |
IRIS Università degli Studi di Palermo |
| Subject Terms: |
semaglutide; obesity; heart failure; Settore MED/49 - Scienze Tecniche Dietetiche Applicate |
| Description: |
Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39181597; info:eu-repo/semantics/altIdentifier/wos/WOS:001308307800001; volume:404; issue:10454; firstpage:773; lastpage:786; numberofpages:14; journal:THE LANCET; https://hdl.handle.net/10447/651714 |
| DOI: |
10.1016/S0140-6736(24)01498-3 |
| Availability: |
https://hdl.handle.net/10447/651714; https://doi.org/10.1016/S0140-6736(24)01498-3 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.6164221F |
| Database: |
BASE |